Learning Objectives: -Assess the clinical implications of patient outcomes in the relapsed/refractory setting to support the rationale for new and emerging treatments in NHL. -Differentiate the mechanisms of action, including therapeutic targets and molecular formats, indications, dosing, and administration requirements of available T-cell mediated treatments in order to tailor personalized treatment strategies. -Select treatment regimens according to the latest clinical evidence including safety and efficacy data in accordance with clinical guideline recommendations. -Identify patients who are candidates for each of the approved CAR T cell therapies or bispecific antibodies. -Evaluate the potential of bridging therapy regimens when utilizing CAR T cell therapy. -Plan strategies to prevent, monitor, and manage adverse events related to treatment with CAR T cell therapy and bispecific antibody therapy to promote optimal patient outcomes and facilitate patient education. -Develop strategies to improve access to novel therapy options in community based practices for the treatment of NHL and HL including patients with barriers to care. -Identify patients with NHL or HL who may benefit from immune checkpoint inhibition and/or CAR T-cell therapies in early-stage, relapsed/refractory disease, or as a bridge to transplant, with consideration to clinical guidelines and latest safety and efficacy data. -Utilize interdisciplinary team-based approaches to ensure the appropriate use of immune checkpoint inhibitors and/or CAR T-cell therapies in NHL and HL, including coordination of care optimization and increased clinical trial enrollment and access to all eligible patients, particularly among those in underrepresented communities.
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://learn.mlieducation.org/courses
- Start Date: 2024-05-15 05:00:00
- End Date: 2024-05-15 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Bristol Myers Squibb - Amount: 66000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Internal Medicine, Medical Oncology